Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression

Schizophrenia Research

Volumn 118, Issue 1-3, 2010, Pages 292-299

  Glantz, Leisa A ^a   Gilmore, John H ^a   Overstreet, David H ^a   Salimi, Kayvon ^a   Lieberman, Jeffrey A ^b   Jarskog, L Fredrik ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Apoptosis; Calmodulin; Cortex; Major depression; Postmortem; Synaptophysin

Indexed keywords

ANTIDEPRESSANT AGENT; CALMODULIN; DESIPRAMINE; DOPAMINE 2 RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 4; SYNAPTOPHYSIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BIPOLAR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; DRUG USE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR DEPRESSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; RAT; SCHIZOPHRENIA; SPRAGUE DAWLEY RAT; TEMPORAL CORTEX; WESTERN BLOTTING;

ADULT; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; APOPTOSIS REGULATORY PROTEINS; BIPOLAR DISORDER; CALMODULIN; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; POSTMORTEM CHANGES; RATS; RATS, MUTANT STRAINS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SYNAPTOPHYSIN; TEMPORAL LOBE;

EID: 77951975936     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.12.027     Document Type: Article

References (53)

1. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W.E., Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 1995, 52(4):258-266.
2. Amar S., Shaltiel G., Mann L., Shamir A., Dean B., Scarr E., Bersudsky Y., Belmaker R.H., Agam G. Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia. Int. J. Neuropsychopharmacol. 2008, 11(2):197-205.
3. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122(2):261-273.
4. Benes F.M., McSparren J., Bird E.D., SanGiovanni J.P., Vincent S.L. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch. Gen. Psychiatry 1991, 48(11):996-1001.
5. Benes F.M., Vincent S.L., Todtenkopf M. The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol. Psychiatry 2001, 50(6):395-406.
6. Benes F.M., Walsh J., Bhattacharyya S., Sheth A., Berretta S. DNA fragmentation decreased in schizophrenia but not bipolar disorder. Arch. Gen. Psychiatry 2003, 60(4):359-364.
7. Benes F.M., Matzilevich D., Burke R.E., Walsh J. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol. Psychiatry 2006, 11(3):241-251.
8. Boghaert E.R., Sells S.F., Walid A.J., Malone P., Williams N.M., Weinstein M.H., Strange R., Rangnekar V.M. Immunohistochemical analysis of the proapoptotic protein Par-4 in normal rat tissues. Cell Growth Differ. 1997, 8(8):881-890.
9. Bonci A., Hopf F.W. The dopamine D2 receptor: new surprises from an old friend. Neuron 2005, 47(3):335-338.
10. Buchsbaum M.S., Christian B.T., Lehrer D.S., Narayanan T.K., Shi B., Mantil J., Kemether E., Oakes T.R., Mukherjee J. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr. Res. 2006, 85(1-3):232-244.
11. Cahn W., Hulshoff Pol H.E., Lems E.B.T.E., van Haren N.E.M., Schnack H.G., van der Linden J.A., Schothorst P.F., van Engeland H., Kahn R.S. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch. Gen. Psychiatry 2002, 59(11):1002-1010.
12. Camandola S., Mattson M.P. Pro-apoptotic action of PAR-4 involves inhibition of NF-kappaB activity and suppression of BCL-2 expression. J. Neurosci. Res. 2000, 61(2):134-139.
13. Chan S.L., Tammariello S.P., Estus S., Mattson M.P. Prostate apoptosis response-4 mediates trophic factor withdrawal-induced apoptosis of hippocampal neurons: actions prior to mitochondrial dysfunction and caspase activation. J. Neurochem. 1999, 73(2):502-512.
14. Chang F., Lee J.T., Navolanic P.M., Steelman L.S., Shelton J.G., Blalock W.L., Franklin R.A., McCubrey J.A. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003, 17(3):590-603.
15. Cotter D.R., Pariante C.M., Everall I.P. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res. Bull. 2001, 55(5):585-595.
16. DeLisi L.E., Sakuma M., Tew W., Kushner M., Hoff A.L., Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. 1997, 74(3):129-140.
17. Duan W., Rangnekar V.M., Mattson M.P. Prostate apoptosis response-4 production in synaptic compartments following apoptotic and excitotoxic insults: evidence for a pivotal role in mitochondrial dysfunction and neuronal degeneration. J. Neurochem. 1999, 72(6):2312-2322.
18. Eastwood S.L., Harrison P.J. Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography. Neuroscience 1995, 69(2):339-343.
19. El-Guendy N., Rangnekar V.M. Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp. Cell Res. 2003, 283(1):51-66.
20. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004, 36(2):131-137.
21. Garey L.J., Ong W.Y., Patel T.S., Kanani M., Davis A., Mortimer A.M., Barnes T.R., Hirsch S.R. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J. Neurol. Neurosurg. Psychiatry 1998, 65(4):446-453.
22. Glantz L.A., Lewis D.A. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch. Gen. Psychiatry 1997, 54(10):943-952.
23. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry 2000, 57(1):65-73.
24. Glantz L.A., Gilmore J.H., Lieberman J.A., Jarskog L.F. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr. Res. 2006, 81(1):47-63.
25. Goldsmith S.K., Shapiro R.M., Joyce J.N. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. Arch. Gen. Psychiatry 1997, 54(7):649-658.
26. Gottfried Y., Rotem A., Klein E., Larisch S. The pro-apoptotic ARTS/Sept4 protein is significantly reduced in post-mortem brains from schizophrenic patients. Schizophr. Res. 2007, 96(1-3):257-266.
27. Guillin O., Abi-Dargham A., Laruelle M. Neurobiology of dopamine in schizophrenia. Int. Rev. Neurobiol. 2007, 78:1-39.
28. Guo Q., Fu W., Xie J., Luo H., Sells S.F., Geddes J.W., Bondada V., Rangnekar V.M., Mattson M.P. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nat. Med. 1998, 4(8):957-962.
29. Guo Q., Xie J., Chang X., Zhang X., Du H. Par-4 is a synaptic protein that regulates neurite outgrowth by altering calcium homeostasis and transcription factor AP-1 activation. Brain Res. 2001, 903(1-2):13-25.
30. Jarskog L.F., Gilmore J.H., Selinger E.S., Lieberman J.A. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol. Psychiatry 2000, 48(7):641-650.
31. Jarskog L.F., Selinger E.S., Lieberman J.A., Gilmore J.H. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am. J. Psychiatry 2004, 161(1):109-115.
32. Karson C.N., Mrak R.E., Schluterman K.O., Sturner W.Q., Sheng J.G., Griffin W.S. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for 'hypofrontality'. Mol. Psychiatry 1999, 4(1):39-45.
33. Kishi T., Ikeda M., Kitajima T., Suzuki T., Yamanouchi Y., Kinoshita Y., Kawashima K., Ozaki N., Iwata N. No association between prostate apoptosis response 4 gene (PAWR) in schizophrenia and mood disorders in a Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B(4):531-534.
34. Lidow M.S., Goldman-Rakic P.S. A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(10):4353-4356.
35. Overstreet D.H., Friedman E., Mathe A.A., Yadid G. The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. Neurosci. Biobehav. Rev. 2005, 29(4-5):739-759.
36. Park S.K., Nguyen M.D., Fischer A., Luke M.P., Affar E.B., Dieffenbach P.B., Tseng H.C., Shi Y., Tsai L.H. Par-4 links dopamine signaling and depression. Cell 2005, 122(2):275-287.
37. Pedersen W.A., Luo H., Kruman I., Kasarskis E., Mattson M.P. The prostate apoptosis response-4 protein participates in motor neuron degeneration in amyotrophic lateral sclerosis. FASEB J. 2000, 14(7):913-924.
38. Perrone-Bizzozero N.I., Sower A.C., Bird E.D., Benowitz L.I., Ivins K.J., Neve R.L. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(24):14182-14187.
39. Pierri J.N., Volk C.L., Auh S., Sampson A., Lewis D.A. Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. Arch. Gen. Psychiatry 2001, 58(5):466-473.
40. Rajkowska G., Selemon L.D., Goldman-Rakic P.S. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch. Gen. Psychiatry 1998, 55(3):215-224.
41. Selemon L.D., Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry 1999, 45(1):17-25.
42. Sells S.F., Wood D.P., Joshi-Barve S.S., Muthukumar S., Jacob R.J., Crist S.A., Humphreys S., Rangnekar V.M. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ. 1994, 5(4):457-466.
43. Sells S.F., Han S.S., Muthukkumar S., Maddiwar N., Johnstone R., Boghaert E., Gillis D., Liu G., Nair P., Monnig S., Collini P., Mattson M.P., Sukhatme V.P., Zimmer S.G., Wood D.P., McRoberts J.W., Shi Y., Rangnekar V.M. Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol. Cell Biol. 1997, 17(7):3823-3832.
44. Stark A.K., Uylings H.B.M., Sanz-Arigita E., Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am. J. Psychiatry 2004, 161(5):882-888.
45. Sun Y., Zhang L., Johnston N.L., Torrey E.F., Yolken R.H. Serial analysis of gene expression in the frontal cortex of patients with bipolar disorder. Br. J. Psychiatry Suppl. 2001, 41:s137-s141.
46. Thompson P.M., Sower A.C., Perrone-Bizzozero N.I. Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia. Biol. Psychiatry 1998, 43(4):239-243.
47. Torrey E.F., Webster M., Knable M., Johnston N., Yolken R.H. The Stanley Foundation Brain Collection and Neuropathology Consortium. Schizophr. Res. 2000, 44(2):151-155.
48. Tuppurainen H., Kuikka J., Viinamaki H., Husso-Saastamoinen M., Bergstrom K., Tiihonen J. Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol. Psychiatry 2003, 8(4):453-455.
49. Wang L.H., Chen J.Y., Liou Y.J., Wang Y.C., Lai I.C., Liao D.L., Chen C.H. Association of missense variants of the PRKC, apoptosis, WT1, regulator (PAWR) gene with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(3):870-875.
50. Won S.J., Kim D.Y., Gwag B.J. Cellular and molecular pathways of ischemic neuronal death. J. Biochem. Mol. Biol. 2002, 35(1):67-86.
51. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 2000, 157(1):16-25.
52. Zawarynski P., Tallerico T., Seeman P., Lee S.P., O'Dowd B.F., George S.R. Dopamine D2 receptor dimers in human and rat brain. FEBS Lett. 1998, 441(3):383-386.
53. Zhao Z., Ksiezak-Reding H., Riggio S., Haroutunian V., Pasinetti G.M. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr. Res. 2006, 84(1):1-14.